FDA approves new pancreatic cancer drug that could extend patients' lives
Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.
Watch CBS News
Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.
What was once a metro Atlanta restaurateur's modest tribute to her late mother has become a multi-million-dollar philanthropy operation saving lives.
